Situation: The public health nurse of a Rural Health Unit (RHU) holds a women's health day on the prevention of noncommunicable diseases (NCDs), including cancer, for residents of a farming barangay. A 34-year-old woman living with human immunodeficiency virus (HIV) is well on antiretroviral therapy. She completed the human papillomavirus (HPV) vaccine series as a schoolgirl and asks how often she needs cervical cancer screening. What should the nurse tell her?

Two rules apply at once. HPV vaccination does not remove the need for screening, because the vaccine does not cover every high-risk type or infection acquired before vaccination. Women with HIV or other immunosuppression are at higher risk of persistent HPV and faster progression, so they follow a more intensive screening schedule than other women, whether or not they are vaccinated.

Clinical context
This question tests how two prevention strategies interact: HPV vaccination and cervical cancer screening in a woman living with HIV. The key is recognizing that immunosuppression changes the natural history of HPV infection, and that vaccination does not eliminate the need for surveillance.

Why option 4 is correct
Women with HIV are at substantially higher risk for persistent high-risk HPV infection and more rapid progression from precancerous lesions to invasive cervical cancer. The immune system normally clears most HPV infections, but HIV-related immune dysfunction—even when partially restored by antiretroviral therapy—impairs that clearance. As a result, screening guidelines consistently recommend shorter intervals for women with HIV than for the general population, regardless of HPV vaccination status.

The evidence supports this directly. A clinical audit from a large Australian HIV center reported that women with HIV are recommended three-yearly cervical cancer screening, compared with five-yearly screening for women without HIV ^[2]. A narrative review focused on sub-Saharan Africa similarly emphasized that women with HIV face a higher cervical cancer burden and require intensified prevention efforts integrated into HIV care ^[3]. A 2009 review noted that even in settings with strong screening programs, the question is not whether women with HIV need screening, but how to optimize its efficiency given their elevated risk .

Why the other options are incorrect
Option 1 — Longer intervals because of the vaccine — is wrong on two counts. First, HPV vaccines do not cover all oncogenic HPV types. Second, vaccination only prevents new infections; it does not treat HPV acquired before vaccination or alter the course of an existing infection. In a woman living with HIV, the risk of persistent infection with a non-vaccine high-risk type remains elevated .

Option 2 — The usual schedule because she completed the vaccine — ignores the independent effect of HIV on cervical carcinogenesis. Vaccination history does not change the screening interval for immunocompromised women. The intensified schedule applies whether or not the woman was vaccinated ^[2][3].

Option 3 — Screening only once CD4 count has recovered — is not consistent with current practice. Screening should not be delayed until immune reconstitution occurs. Women with HIV are screened on a defined schedule based on HIV status, not on a specific CD4 threshold. Delaying screening would miss the window for detecting and treating precancerous lesions early .

Pathophysiology link
HPV infects basal epithelial cells of the cervical transformation zone. In immunocompetent individuals, cell-mediated immunity clears most infections within 1–2 years. In HIV infection, depletion and dysfunction of CD4+ T cells weaken this response, allowing high-risk HPV types to persist. Persistent infection is the prerequisite for integration of viral oncogenes (E6/E7), which inactivate tumor suppressors p53 and Rb and drive malignant transformation. Antiretroviral therapy improves immune function but does not fully restore HPV-specific immunity, which is why women with HIV remain at elevated risk even when virologically suppressed .

Screening schedule comparison

Population	Recommended interval	Rationale
Women without HIV, general population	5 years (HPV-based testing)	Lower risk of persistent HPV and progression
Women with HIV	3 years or more frequent	Higher prevalence of persistent HPV, faster progression to CIN and cancer
Women with HIV who completed HPV vaccine	Same intensified schedule as other women with HIV	Vaccine does not cover all high-risk types or pre-existing infection

Watch out! HPV vaccination status never lengthens the screening interval for a woman with HIV. The two interventions are complementary, not interchangeable.

Key point! Immunosuppression, not vaccination history, determines the screening schedule for cervical cancer in women living with HIV. The correct response is a more frequent schedule than for women without HIV ^[2][3].